Display options
Cite
Abdurahman A, Anwar J, Turghun A, et al. Epidermal growth factor receptor gene mutation status and its association with clinical characteristics and tumor markers in non-small-cell lung cancer patients in Northwest China. Mol Clin Oncol. 2015;3(4):847-850doi: 10.3892/mco.2015.564.
Abdurahman, A., Anwar, J., Turghun, A., Niyaz, M., Zhang, L., & Awut, I. (2015). Epidermal growth factor receptor gene mutation status and its association with clinical characteristics and tumor markers in non-small-cell lung cancer patients in Northwest China. Molecular and clinical oncology, 3(4), 847-850. https://doi.org/10.3892/mco.2015.564
Abdurahman, Ablajan, et al. "Epidermal growth factor receptor gene mutation status and its association with clinical characteristics and tumor markers in non-small-cell lung cancer patients in Northwest China." Molecular and clinical oncology vol. 3,4 (2015): 847-850. doi: https://doi.org/10.3892/mco.2015.564
Abdurahman A, Anwar J, Turghun A, Niyaz M, Zhang L, Awut I. Epidermal growth factor receptor gene mutation status and its association with clinical characteristics and tumor markers in non-small-cell lung cancer patients in Northwest China. Mol Clin Oncol. 2015 Jul;3(4):847-850. doi: 10.3892/mco.2015.564. Epub 2015 May 11. PMID: 26171194; PMCID: PMC4486793.
Copy Download .nbib Format: NLM
Share it on

Mol Clin Oncol. 2015 Jul;3(4):847-850. doi: 10.3892/mco.2015.564. Epub 2015 May 11.

Epidermal growth factor receptor gene mutation status and its association with clinical characteristics and tumor markers in non-small-cell lung cancer patients in Northwest China.

Molecular and clinical oncology

Ablajan Abdurahman, Jurat Anwar, Abdugheni Turghun, Madiniyet Niyaz, Liwei Zhang, Idiris Awut

Affiliations

  1. Department of Thoracic Surgery, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830054, P.R. China.
  2. Clinical Research Institute, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830054, P.R. China.

PMID: 26171194 PMCID: PMC4486793 DOI: 10.3892/mco.2015.564

Abstract

This study was conducted to investigate the mutation status of epidermal growth factor receptor (EGFR) and its association with clinical characteristics and tumor markers in non-small-cell lung cancer (NSCLC) patients from the Xinjiang Uygur Autonomous Region in China. We enrolled 51 cases of NSCLC patients who received radical surgical treatment in the First Affiliated Hospital of Xinjiang Medical University. Quantitative polymerase chain reaction was applied to detect exons 18, 19, 20 and 21 of the EGFR gene in tumor tissues. Multiple tumor markers, including carcinoembryonic antigen (CEA), were assessed preoperatively. The EGFR-positive rate was 49.02% (25/51), with a mutation rate of 8% (2/25) in exon 18, 52% (13/51) in exon 19, 40% (10/51) in exon 21 and no mutations in exon 20. The positive mutation rate in men and women was 37.5% (12/32) and 68.42%, respectively (13/19), with a statistically significantly higher rate in women (P<0.05). There were also statistically significant differences among adenocarcinoma, adenosquamous carcinoma and squamous cell carcinoma cases (P<0.05), while no statistically significant differences were observed in adenocarcinoma cases regarding degree of differentiation, lymph node metastasis and TNM stage (P>0.05). There was a statistically significant association between the EGFR gene mutation status and the preoperative serum CEA level (P<0.05). The mutation rate of the EGFR gene was 68.42% in female lung adenocarcinoma patients, which supports the application of targeted therapy in such cases. However, whether it is possible to obtain information regarding targeted therapy through measuring the level of serum CEA for NSCLC patients with unknown EGFR mutation status requires further investigation through related studies including a higher number of cases.

Keywords: Xinjiang; epidermal growth factor receptor; non-small-cell lung cancer; targeted therapy; tumor marker

References

  1. J Thorac Oncol. 2010 Oct;5(10):1524-8 - PubMed
  2. Lung Cancer. 2013 Jan;79(1):8-13 - PubMed
  3. J Thorac Oncol. 2007 May;2(5):430-9 - PubMed
  4. Cancer Lett. 2006 Aug 8;239(2):292-7 - PubMed
  5. Cancer. 2007 Dec 15;110(12):2793-8 - PubMed
  6. Asian Pac J Cancer Prev. 2013;14(7):4369-71 - PubMed
  7. J Thorac Oncol. 2013 Jan;8(1):45-51 - PubMed
  8. Annu Rev Pathol. 2011;6:49-69 - PubMed
  9. Ann Oncol. 2007 Jan;18(1):99-103 - PubMed
  10. Chin J Cancer Res. 2014 Feb;26(1):89-94 - PubMed
  11. J Thorac Oncol. 2008 Dec;3(12 ):1446-53 - PubMed
  12. Clin Lung Cancer. 2011 May;12(3):172-9 - PubMed
  13. Oncol Rep. 2009 Oct;22(4):683-91 - PubMed
  14. Zhonghua Bing Li Xue Za Zhi. 2011 Oct;40(10):671-4 - PubMed
  15. J Clin Oncol. 2008 Sep 10;26(26):4268-75 - PubMed
  16. BMJ Open. 2013 Apr 03;3(4):null - PubMed
  17. Ann Oncol. 2013 May;24(5):1319-25 - PubMed

Publication Types